2026-03-01T23:20:32Z https://njump.cloud.vinney.xyz Dr. Lucky Tran :verified: https://njump.cloud.vinney.xyz/npub1fvus6ey0wswu2y4mfycc7h5ckz6h72h6vmhczz3lyzynjg5egdlqdrnhwd https://cdn.masto.host/medmastodoncom/accounts/avatars/109/300/367/550/582/260/original/5380622bc8bd2ae6.jpg https://cdn.masto.host/medmastodoncom/accounts/avatars/109/300/367/550/582/260/original/5380622bc8bd2ae6.jpg https://njump.cloud.vinney.xyz/nevent1qqsyj9xfmnneyqfj9gfq9njjyytgmthjarw82ttshmv7v2va4zs8vjqzyp9njrty3a6pm3gjhdynrr67nzct2le2lfnwlqg28usgjwfzn9phu5yk4jq A new drug described as “the closest we have ever been to an HIV vaccine” could be sold for $40 a year and still make 30% profit, but is currently being sold by pharma companies for $42,250. Absolutely criminal. <br/><br/><a href="https://www.theguardian.com/global-development/article/2024/jul/23/hiv-aids-prevention-vaccine-lenacapavir-sunlenca-pharmaceuticals-gilead-generic-licensing">https://www.theguardian.com/global-development/article/2024/jul/23/hiv-aids-prevention-vaccine-lenacapavir-sunlenca-pharmaceuticals-gilead-generic-licensing</a> 2024-07-23T21:13:28Z